Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
Active, not recruiting · NCT03689699 · Registry updated 2025-04-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate adenocarcinoma, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-04-29 | NCT03689699 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Mark Stein | 3 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Columbia University Irving Medical Center | New York | United States | 234 |
| Sidney Kimmel Cancer Center- Thomas Jefferson University | Philadelphia | United States | 1 |
| Weill Cornell Medical Center | New York | United States | 8 |
| Winship Cancer Institute, Emory University | Atlanta | United States | 47 |